MicroPort EP(SH:688351) Zhi Tong Cai Jing·2026-02-11 08:48Core Viewpoint - The company reported a total revenue of 465 million yuan for the year 2025, marking a year-on-year increase of 12.43%, while the net profit attributable to the parent company decreased by 1.76% to 51.15 million yuan [1] Group 1: International Expansion - The company has deepened its overseas layout, achieving significant results in business development, with overseas revenue growing by over 40% year-on-year, now accounting for more than 30% of total revenue [1] - The high-end pressure monitoring radiofrequency ablation catheter has been commercialized in over 20 countries, and the cryoablation system has successfully obtained EU certification, with commercial applications in Germany, Turkey, and Greece [1] - The company actively participated in major international academic conferences, showcasing its "electric fire ice" comprehensive solution, which has gained widespread attention and recognition in the industry [1] Group 2: Domestic Business and Product Innovation - The company continues to focus on breakthroughs in high-end procedures and product innovation, with the usage of pressure monitoring radiofrequency ablation catheters increasing by over 70% year-on-year [2] - The company remains a leader in industry technology, with the approval of the PulseMagic TrueForce disposable pressure monitoring cardiac pulsed electric field ablation catheter, which is the first in China to feature a saline infusion function [2] - The collaboration with the affiliated company, Shangyang Medical, on the PulseMagic Spiral catheter is expected to create a complete product matrix in the pulsed ablation field, playing a key role in the iteration of cardiac electrophysiology technology and domestic replacement [2]